Kornimate/medical-research-clean huggingface dataset:
motivational interviewing to improve treatment engagement and outcome in subjects seeking treatment for substance abuse - 1

Conditions: Substance-Related Disorders

Summary: the purpose of this study is to assess motivational interviewing (mi) to improve treatment engagement and outcome in subjects seeking treatment for substance abuse.

participants seeking treatment at the participating ctps will be randomly assigned to either "standard" or "met/mi" treatment, with a 1- and 3-month follow-up. primary outcome measures will include (1) treatment retention (e.g., number of sessions/weeks completed, the rate of patients completing 3 or more subsequent sessions, and (2) substance use (e.g., urinalyses, days of opioid, cocaine, marijuana, alcohol use, rates of abstinence). secondary outcomes will include motivation, psychosocial functioning, hiv risk behaviors, treatment utilization, and patient satisfaction. process assessments will include measures of the working alliance as well as therapist adherence/competence ratings which will evaluate how effectively met/mi was implemented. participating ctps will implement one of two independent protocols, depending on which is the best suited or feasible for the intake procedures at their clinic. thus, following an invitation to participate, explanation of the study, and provision of informed consent, patients would complete a brief assessment battery followed by either:1) random assignment to 3 individual sessions of standard treatment (treatment as usual) at the program versus 3 individual sessions of met; or 2) random assignment to 1 individual standard assessment/evaluation session.

Eligibility criteria:
inclusion criteria: individuals will be eligible for the protocol who: a)are seeking outpatient treatment for any substance use disorder. b)are 18 years of age or older. c)are willing to participate in the protocol (e.g., to be randomized to treatment, be contacted for follow-up assessment, to have their sessions audiotaped). d)are able to understand and provide written informed consent. exclusion criteria: individuals will be excluded who: a)are not sufficiently medically or psychiatrically stable to participate in outpatient treatment. b)are seeking detoxification only, methadone maintenance, or residential inpatient treatment.

Keywords: substance use disorders
lorcaserin in the treatment of cocaine use disorder

Conditions: Cocaine-Related Disorders

Summary: the objective of this study is to evaluate the efficacy and safety of lorcaserin in the treatment of cocaine use disorder.

this is a 19-week, multi-center, randomized, phase 2 clinical study comparing the efficacy of lorcaserin (10mg, b.i.d) to matched placebo in the treatment of cocaine use disorder. up to 3 weeks will be allowed for the screening period and a 13-week treatment phase, with a 3-week follow-up period, with scheduled visits during study weeks 14 and 16.

Eligibility criteria:
inclusion criteria: * has a dsm-5 diagnosis of current cocaine use disorder as verified by the structured clinical interview for dsm-5 * is seeking treatment for cocaine use disorder * is able to understand and provide written informed consent * has used cocaine on at least 1 day in the last 30 days prior to screening * has completed all psychological assessments and procedures during the screening period * if female, not pregnant, lactating, unable to conceive or must agree to use an acceptable method of birth control * has a total body weight greater than 110 pounds and body mass index greater than 20 exclusion criteria: * contact site for more information

Keywords: cocaine use disorder
study of the incidence of sars-cov-2 infection (covid-19)

Conditions: Coronavirus Infections

Summary: this is a prospective observational cohort study that will define the prevalence and incidence of ca-sars-cov2 infection using serological and pcr tests in a group of subjects during deconfinement. the team wishes to include approximately 1000 subjects in this study. the health crisis through containment has also created unprecedented environmental conditions with the very clear decrease in economic activities and a consequent decrease in exposure to the main air pollutants. the aim is therefore to carry out a case-control study in which each subject will be his or her own control in unexposed condition (to pm2.5, pm10, no...) then exposed (after the recovery of economic activity and the usual levels of air pollutants) and to measure the impact of these pollutants on the immune system and epigenetic markers taking into account seasonality. the occurrence of infectious, cardiovascular, allergic and autoimmune events will then be measured according to the immunological profiles measured at inclusion.


Eligibility criteria:
inclusion criteria: * any major subject, voluntary, exposed to the public from 11 may 2020 informed of the study by partner institutions (departmental council 06), affiliated to a social security scheme, exclusion criteria: * subject protected by law under tutorship or guardianship, or who cannot participate in a clinical study under the terms of article l. 1121-16 of the french public health code
effect of coadministration of itraconazole on the pharmacokinetics of crd-740

Conditions: Clinical Pharmacology; Pharmacokinetics; Cardiovascular Diseases; Heart Failure

Summary: this is a phase 1, single-site, open-label, fixed sequence crossover study to investigate the effect of coadministration of itraconazole on the pharmacokinetics of crd-740 in healthy male and female subjects. subjects will be admitted into the study site on day -1 and will be confined to the study site until discharge on day 16. subjects will receive crd-740 orally on days 1 and 10. itraconazole will be given once daily, orally, on days 7 through 15.


Eligibility criteria:
inclusion criteria: 1. males or females, of any race, between 18 and 55 years of age, inclusive. 2. body mass index between 18.0 and 32.0 kg/m2, inclusive. 3. in good health, determined by no clinically significant findings as assessed by the investigator. 4. adhere to all contraception criteria. exclusion criteria: 1. significant medical history as determined by the investigator. 2. history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, including itraconazole, unless approved by the investigator (or designee). 3. history of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed). 4. any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the investigator. 5. history or presence of an abnormal ecg. 6. use or intend to use any medications/products/herbal remedies known to alter drug absorption, metabolism, or elimination processes, including st. john's wort, within 30 days prior to check-in, unless deemed acceptable by the investigator (or designee). 7. drugs affecting cyp3a4 should be refrained from use for 3 weeks, or 5 half-lives (whichever is longer), prior to check-in through to follow-up. 8. positive urine drug screen at screening or positive alcohol breath test result or positive urine drug screen at check-in.21. history of alcoholism or drug/chemical abuse within 12 months prior to check-in. 9. ingestion of poppy seed, seville orange, or grapefruit containing foods or beverages within 7 days prior to check-in.
gpc3/mesothelin-car-γδt cells against cancers

Conditions: Pancreas Cancer; Lung Cancer; Liver Cancer; Mesothelioma; CAR-T Cell Therapy; Solid Tumor, Adult

Summary: the third generation of gpc3/mesothelin targeted car-γδt cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. clinical studies will be performed to test anti-cancer function of the car-γδt cells for immunotherapy of human cancer patients with gpc3 or mesothelin expressions. in this phase i study, the safety, tolerance, and preliminary efficacy of the gpc3/mesothelin-car-γδt cell immunotherapy on human cancers will firstly be evaluated.

1. choose appropriate patients with advanced solid cancers, with written consent for this study; 2. perform biopsy to determine the expression of gpc3 or mesothelin of the tumors by western blotting or ihc; 3. collect blood from the patients and isolate mononuclear cells, select and grow γδt cells and transfect the γδt cells with gpc3 or mesothelin targeting car, amplify the transfected γδt cells as needed, test the quality and killing activity of the car-γδt cells and then transfer them back the patients via systemic or local injections, and follow up closely to collect related results as required; 4. to enhance the killing capability, cotreatment the patients with pd1/pdl1/ctla4 antibodies may be applied; 5. evaluate the clinical results as needed.

Eligibility criteria:
inclusion criteria: 1. patients with advanced cancer that expresses gpc3 or mesothelin protein; 2. life expectancy \>12 weeks; 3. adequate heart, lung, liver, kidney, and blood function; 4. available autologous transduced t cells with greater than or equal to 20% expression of gpc3/mesothelin-car determined by flow-cytometry and killing of mesothelin-positive targets greater than or equal to 20% in cytotoxicity assay; 5. informed consent explained to, understood by and signed by patient/guardian. patient/guardian given copy of informed consent. - exclusion criteria: 1. had accepted gene therapy before; 2. severe virus infection such as hbv, hcv, hiv, et al; 3. known hiv positivity; 4. active infectious disease related to bacteria, virus,fungi,et al; 5. other severe diseases that the investigators consider not appropriate; 6. pregnant or lactating women; 7. systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day); 8. other conditions that the investigators consider not appropriate. -

Keywords: solid tumor car-γδt γδt gpc3 mesothelin
engaging men in weight loss with a game-based mhealth and neurotraining program

Conditions: Obesity; Weight Loss

Summary: men in the united states have an exceptionally high prevalence of overweight and obesity, i.e., 71.3%, and 42% of men are currently attempting weight loss. however, men are dramatically underrepresented in weight loss programs. attempts to modestly adapt standard weight loss programs have seen only minimal success. mobile applications (mhealth apps) have attractive features, but have low male enrollment and poor efficacy as conventionally delivered. a gamified mhealth program offers the possibility of engaging men and enhancing efficacy given that (1) video gaming is highly appealing to men; (2) gamification features (e.g., digital rewards for attaining "streaks" and milestones, competition) are known enhance enjoyment and motivation and facilitate desired behaviors; and (3) "neurotraining" video games featuring repetitive action mechanics, adaptive difficulty, and feedback can train inhibitory control, a basic brain capacity to inhibit intrinsically-generated approach responses that is strongly linked to body mass and the consumption of high-calorie foods. this project evaluates long-term engagement and outcomes of a professionally-designed, game-based weight loss program. as such, 228 overweight men will be randomized to: (1) a 12-month mhealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining, or (2) a fully-gamified version of this same program, comprised of a behavior change program featuring team-based competition, digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game. aims include evaluating the efficacy of the gamified program in terms of weight loss, diet and physical activity at 12 months, as well as evaluating hypothesized mediators (inhibitory control and engagement), (enjoyment and compliance) and moderators (baseline frequency of video game play and implicit preferences for inhibitory control training-targeted foods).


Eligibility criteria:
inclusion criteria: * individuals must be of overweight or obese bmi (25-50 kg/m) * individuals must be adults (aged 18-65) * able to engage in physical activity (defined as walking two city blocks without stopping) * individuals must also provide consent for the research team to contact their personal physician, if necessary, to provide clearance for the prescribed level of physical activity (i.e., walking) or to consult about rapid weight loss * have moderate-to-high implicit preference for high-calorie foods * satisfactory completion of all enrollment procedures\] exclusion criteria: * medical condition (e.g., cancer, type i diabetes, renal failure), heavy alcohol use, or psychiatric condition (e.g., active substance abuse, eating disorder) that may pose a risk to the participant during intervention or cause a change in weight * recently began or changed the dosage of medication that can cause significant change in weight * history of bariatric surgery * weight loss of ≥ 5% in the previous 3 months
determination of body awareness and the functional movement in patients with copd

Conditions: Pulmonary Disease, Chronic Obstructive; Postural; Defect; Movement, Abnormal; Pain

Summary: the aim of this study is to investigate body awareness and functional movement in patients with chronic obstructive pulmonary disease (copd) compared to healthy controls.

it is aimed at investigating body awareness, and functional movement, and related factors in patients with copd. the secondary purpose is to determine correlations between body awareness and functional movement, respiratory muscle strength and endurance, daily living activities, posture, and pain threshold in this study. the determination of correlations between functional movement, respiratory pattern, and functional exercise capacity is also purposed. in accordance with these purposes, at least 30 patients with copd will be included and at least 30 healthy controls will be included. tests and questionnaires will be used in order to determine the severity of disease. lung function test and respiratory muscle strength and endurance test will be performed. six minute walk test will be performed for functional exercise capacity. to evaluate posture, the corbin postural assessment scale will be used. pain and pain threshold will be assessed via visual analog scale and an algometer, respectively. body awareness rating questionnaire will be used for evaluating body awareness. to evaluate daily living activities, glittre activities of daily living test will be used. the functional movement screen test will be used for functional movement analysis. according to the results to be obtained, body awareness and functional movement will be determined in patients with copd. it will guide professional working in this field.

Eligibility criteria:
inclusion criteria for chronic obstructive pulmonary disease group * being under 55 years old * to be literate, * having volunteered to participate in the research, * stage 1-2-3-4 according to the classification of airflow limitation in copd (gold) system, * being clinically stable for the last 2 weeks. exclusion criteria for chronic obstructive pulmonary disease group * having history of lung cancer, sarcoidosis, tuberculosis and/or lung surgery, * communication problems, * having a severe psychiatric disorder. inclusion criteria for healthy control group * not having any cardiopulmonary system disease or chronic systemic disease, * to be literate, * being under 55 years old * be willing to participate in the study. * not having balance problems, musculoskeletal, neurological and psychiatric disorders that could prevent performing the test procedures.
prospective epidemiological study of upper limb venous thrombosis

Conditions: Venous Thrombosis

Summary: venous thrombosis of the upper limb is one of the manifestations of venous thromboembolic disease. the epidemiology and management of upper limb venous thrombosis is much less well documented than that of lower limb venous thrombosis. the investigators wished to provide epidemiological data concerning upper limb venous thrombosis in the hospital setting. the researchers would like to know the prevalence of this pathology among patients hospitalized in a university hospital center. in order to obtain this prevalence, the investigators wish to carry out a monocentric cross-sectional descriptive study.

venous thrombosis of the upper limb is one of the manifestations of venous thromboembolic disease. the epidemiology and management of upper limb venous thrombosis is much less well documented than that of lower limb venous thrombosis. the investigators wished to provide epidemiological data concerning upper limb venous thrombosis in the hospital setting. the researchers would like to know the prevalence of this pathology among patients hospitalized in a university hospital center. in order to obtain this prevalence, the investigators wish to carry out a monocentric cross-sectional descriptive study. the main objective of the study is to define the prevalence of upper limb venous thrombosis in patients hospitalized at nantes university hospital. the secondary objectives are to describe the epidemiology according to the patient's hospitalization sector or the endovenous medical devices used. another secondary objective is to describe the clinical signs associated with thromboses and their characteristics. the investigators wish to include major patients hospitalized at the nantes university hospital in different sectors (medical, surgical, intensive care units). after collecting the patient's non-opposition, reseachers will carry out a venous duplex ultrasonography of the upper limbs. data concerning the hospitalization unit, the patient's comorbidities, the presence of venous tracts or other endo-venous devices, clinical signs and duplex ultrasonography data will be collected using a standardized collection grid.

Eligibility criteria:
inclusion criteria : * patient (major, pregnant woman) hospitalized in a department of the nantes university hospital and accepting participation in this research exclusion criteria : * opposition to the completion of the review, minors, adults under guardianship.

Keywords: upper limb venous thrombosis prevalence epidemiology
the comparative study of oct，gemstone ct and 320-detector row spiral ct for evaluating restenosis of coronary artery stent

Conditions: Coronary Heart Disease

Summary: in-stent restenosis is a major reason of coronary heart disease recurrence .even in drug eluting stent(des), restenosis rate could be up to 10% in diabetes and complex lesions though it was about 3-5% in general. it is particularly important that in-stent restenosis after implantation was early diagnosed and detected. the evaluation of oct imaging is more accurate for narrow area calculation, more clear for narrow organization structure and more specific for detecting tissue types.it is currently the best way for restenosis histologic diagnosis.but it has many weakness such as the higher cost,an invasive test, expensive instrument, relatively complicated to operate,and etc.in this study, oct image was regard as the "gold standard" of stent restenosis. the improvement of spatial resolution of gemstone ct can effectively improve the imaging quality and the measurement's accuracy of coronary artery stents.the diagnostic value of in-stent restenosis of gemstone ct is higher than of the 320-detector row spiral ct. to a certain extent, the gemstone ct can replace oct for examining the in-stent restenosis. this study will examine the degree of in-stent restenosis by the gemstone ct and the 320-detector row spiral ct and compare the two ways on the basis of the result of oct.


Eligibility criteria:
inclusion criteria: 1. age 20-80， all genders 2. unlimited time of implantation of coronary artery stents 3. myocardial ischemia symptoms such as chest tightness and/or chest pain in patients after stent implantation 4. no clinical symptoms, but myocardial ischemia suggested by other noninvasive tests 5. routine re-testing 9-12 months after stent implantation. exclusion criteria: 1. renal insufficiency (serum creatinine \> 120 umol/l) 2. allergy of contrast 3. severe heart failure 4. uncontrollable heart rate or contraindication of taking metoprolol 5. unstable condition 6. the ventricular rate beyond 70 beats / min and irregular rhythm after adjusting.

Keywords: gemstone ct 320-detector row spiral ct optical coherence tomography(oct) in-stent restenosis coronary heart disease
transcatheter aortic valve replacement single center registry in chinese population

Conditions: Symptomatic Aortic Stenosis

Summary: the purpose of this study is to evaluate the safety and effectiveness of transcatheter aortic valve replacement in chinese population.

subjects enrolled are those who undergo physical exams and screening tests and were classified as a patient with symptomatic aortic stenosis or severe aortic regurgitation. they are then performed transcatheter aortic valve replacement.

Eligibility criteria:
inclusion criteria: * patients with symptomatic aortic stenosis/regurgitation * subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. * the subject agrees to comply with specified follow-up evaluations and to return to the investigational site where the procedure was performed. * patients are technical and anatomical eligible for interventions exclusion criteria: * a known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin heparin (hit/hitts) and bivalirudin nitinol (titanium or nickel) ticlopidine and clopidogrel contrast media * subject refuses a blood transfusion. * other medical, social, or psychological conditions that in the opinion of an investigator precludes the subject from appropriate consent. * life expectancy is less than one year
tranexamic acid in orthopaedic trauma surgery

Conditions: Blood Loss; Trauma; Fracture; Surgery

Summary: tranexamic acid is an antifibrinolytic drug that has been used to decrease post-operative blood loss. this study is a prospective, randomized controlled trial investigating the use of tranexamic acid in fracture surgery around the hip and knee, in which significant blood loss (\>300ml) is expected. the hypothesis of this study is that tranexamic acid will be associated with a decrease in post-operative blood loss, as well as a decreased need for allogenic blood transfusion, in patients who have fracture surgery around the hip and knee.


Eligibility criteria:
inclusion criteria: * patients with isolated fractures of the pelvic ring, acetabulum, femur or tibia that will require open reduction and internal fixation * expected blood loss is greater than 300 ml * age ≥ 18 * skeletal maturity exclusion criteria: * pregnant or breastfeeding * patients taking oral contraceptives * contraindication to venous thromboembolic event (vte) prophylaxis (intracranial, intrathoracic, intra-abdominal bleeding or spine fractures) * patients requiring operative intervention for other injuries (orthopaedic or non-orthopaedic) * known hypercoagulable state including history of prescribed anti-coagulation (warfarin, plavix, low molecular weight heparin) * renal insufficiency (creatinine greater than 1.5mg/dl) * open fractures

Keywords: tranexamic acid orthopaedic trauma pelvic fracture hip fracture femur fracture blood loss